Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study

<div>Patient enrollment, disposition, and follow-up. DMD: disease-modifying drug, GA: glatiramer acetate, IFN: interferon, im: intramuscular, and sc: subcutaneous.</div>

Multiple Sclerosis International

fig1

Figure 1

Figure 1: Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study 

Figure 1 | Disease-Modifying Drugs Reduce Cortical Lesion Accumulation and Atrophy Progression in Relapsing-Remitting Multiple Sclerosis: Results from a 48-Month Extension Study 